Removal of Novarsc by Domestic Hospital

Published: 2005-01-18 06:58:00

Updated: 2005-01-18 06:58:00

An industry source reported last week that the Severance Hospital Group has removed Pfizer Korea's Novarsc, an anti-hypertension drug, from its available group of prescription-based treatments.

According to the source, the Severance Hospital Group excluded Pfizer Korea's Novarsc in the annual ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK